Drug intelligence / Profile preview

SNIPR-GOUT

Development stage: Preclinical
Lead developer: SNIPR Biome
Modality: Gene Therapies

Overview

SNIPR-GOUT is a gene therapy candidate initially developed by SNIPR Biome ApS for the treatment of gout. It is currently in the discovery phase of development. The drug targets congenital disorders, endocrinology and metabolic diseases, as well as skin and musculoskeletal diseases, with its primary active indication being gout. The specific mechanism of action has not been publicly detailed beyond its classification as a gene therapy[1].

Targets

bacterial dsDNA (Bacterial double-stranded DNA)

Beyond the preview

Go deeper on SNIPR-GOUT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNIPR-GOUT.

Explore the full profile